Multimodal imaging measures to assess synaptic dysfunction in Alzheimer's disease
评估阿尔茨海默病突触功能障碍的多模态成像方法
基本信息
- 批准号:10448946
- 负责人:
- 金额:$ 48.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAlzheimer&aposs disease therapyAmyloidAmyloid beta-ProteinBasic ScienceBindingBiological AssayBiological MarkersBrainClinicalClinical TrialsCognitionCognitiveCognitive deficitsCoupledDataDementiaDepositionDetectionDevelopmentDiseaseEarly InterventionElectrophysiology (science)EventExcitatory SynapseFunctional disorderFunding AgencyFutureGenerationsGlycoproteinsGoalsHalf-LifeHumanImaging TechniquesImpaired cognitionImpairmentIndividualInferiorInhibitory SynapseInvestigationLanguageLigandsLinkMagnetic Resonance ImagingMagnetoencephalographyMathematicsMeasuresMedialMediatingMemoryModelingMolecularMultimodal ImagingNeurologicNeuronsNeuropsychologyParticipantPathologicPathologic ProcessesPathologyPatientsPhysiologyPilot ProjectsPopulationPositron-Emission TomographyPropertyProteinsRecordsResearchResolutionResourcesRestSenile PlaquesSynapsesSynaptic VesiclesTechniquesTechnologyTemporal LobeTherapeutic InterventionTimeToxic effectTracerTransgenic OrganismsVisuospatialabeta accumulationabeta depositionage related neurodegenerationbasecingulate cortexclinical investigationcognitive functioncohortcostdensitydesignearly detection biomarkersentorhinal cortexhuman imaginghuman subjectimaging propertiesimaging studyin vivoindexinginnovationinsightmild cognitive impairmentmolecular imagingmultimodalityneocorticalneuroimagingneurophysiologynovelradioligandrecruitrelating to nervous systemresearch clinical testingspatiotemporalsynaptic failuresynaptic functiontau Proteinstau aggregationtherapeutically effectiveuptakeβ-amyloid burden
项目摘要
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder, a relentless and fatal
condition of progressive cognitive deficits. The urgency to find a cure for AD has never been stronger. Synaptic
dysfunction and synapse loss are core deficits in AD pathophysiology. A better understanding of synaptic
dysfunction in AD is imperative to develop effective therapeutic interventions. In this R21, we propose a
multimodal imaging study combining structural and functional synaptic measures simultaneously to characterize
synaptic failure in patients with AD. The multimodal composition of our study includes magnetoencephalography
(MEG) to probe synapse physiology and positron emission tomography (PET) to probe synapse density,
together with in-vivo quantification of amyloid (Aβ) and tau depositions. This proposal represents one of the very
first to combine two sophisticated technologies to study synaptic failure in AD. On one hand, MEG provides
quantitative spectral signatures of neural oscillations which represents the most direct, non-invasive, measures
of neuronal and synaptic function in the human brain. Combining the fine spatiotemporal resolution of MEG
spectral analyses with mathematical application of neural mass model (NMM) is a powerful technique to examine
neuronal level details from non-invasive neuroimaging in human subjects. On the other hand, radioligands that
bind to the synaptic vesicle glycoprotein 2A (SV2A) has recently become available to measure in-vivo synaptic
density in the human brain. Here we propose to use a new second generation SV2A ligand, 18F-SynVesT-1, for
the first time in AD research. Defining the relationships between synaptic density and synapse physiology and
their specific relationships to Aβ and tau will broaden the current conceptualizations of AD pathophysiology and
provide novel synaptic biomarkers for early interventional clinical trials. We will conduct a cross sectional pilot
study of 45 participants: 25 Aβ-positive mild cognitive impairment (MCI) and mild-AD-dementia (CDR<1), and
20 age-matched cognitively unimpaired individuals (10 Aβ-negative and 10 Aβ-positive). All participants will
undergo resting state MEG, structural MRI, 3-tracer PET imaging for SV2A (18F-18F-SynVesT-1), Aβ
(florbetaben), and tau (flortaucipir), and complete cognitive and neuropsychological assessments. Our central
hypothesis is that excitatory and inhibitory neuronal deficits will be correlated with reduced synaptic density (18F-
SynVesT-1), and with Aβ and tau depositions (florbetaben and flortaucipir, respectively) in early clinical stage of
AD. We will address two key aims. In Aim 1, we will determine the relationship between impaired synapse
physiology (MEG and NMM) and synapse density (18F-SynVesT-1 retention) in AD. In Aim 2, we will Examine
the associations between binding deficits of 18F-SynVesT-1 PET and AD pathophysiology and cognitive
impairments in early clinical stage AD patients. This project will generate crucial data to define synaptic failure
in patients with AD and preliminary data to design future studies linking clinical investigations in AD patients to
mechanistic findings from basic science.
阿尔茨海默病(AD)是最常见的与年龄相关的神经退行性疾病,
进行性认知缺陷的情况。寻找治疗AD的方法的紧迫性从未如此强烈。突触
功能障碍和突触丧失是AD病理生理学的核心缺陷。更好地理解突触
因此,开发有效的治疗干预措施势在必行。在这个R21中,我们提出了一个
多模态成像研究结合结构和功能突触的措施,同时表征
AD患者的突触功能障碍。我们研究的多模态组成包括脑磁图
(MEG)以探测突触生理学和正电子发射断层扫描(PET)以探测突触密度,
以及淀粉样蛋白(A β)和tau沉积的体内定量。这一建议代表了一个非常
第一个将两种复杂的技术联合收割机结合起来研究AD中的突触失效。一方面,MEG提供
神经振荡的定量光谱特征,其代表了最直接、非侵入性的测量
人类大脑中神经元和突触的功能。结合脑磁图精细的时空分辨率
光谱分析与神经质量模型(NMM)的数学应用是一种强大的技术,
来自人类受试者的非侵入性神经成像的神经元水平细节。另一方面,
与突触囊泡结合的糖蛋白2A(SV2A)最近可用于测量体内突触
大脑中的密度。在这里,我们建议使用新的第二代SV2A配体,18F-SynVesT-1,
这是AD研究的第一次。定义突触密度和突触生理学之间的关系,
它们与A β和tau蛋白的特异性关系将拓宽目前AD病理生理学的概念,
为早期干预性临床试验提供新的突触生物标志物。我们将进行一次横向试点
45名参与者的研究:25名A β阳性轻度认知障碍(MCI)和轻度AD痴呆(CDR <1),
20名年龄匹配的认知未受损个体(10名A β阴性和10名A β阳性)。所有参与者将
接受静息状态MEG、结构MRI、SV2A(18F-18F-SynVesT-1)、A β 3示踪剂PET成像
(florbetaben)和tau(flortaucipir),并完成认知和神经心理学评估。我们的中央
假设兴奋性和抑制性神经元缺陷与突触密度降低相关(18F-
SynVesT-1),并与A β和tau沉积(分别为florbetaben和flortaucipir)在早期临床阶段,
ad.我们将致力于两个关键目标。在目标1中,我们将确定受损的突触之间的关系
生理学(MEG和NMM)和突触密度(18F-SynVesT-1保留)。在目标2中,我们将检查
18F-SynVesT-1 PET结合缺陷与AD病理生理学和认知功能之间的关系
早期临床阶段AD患者的损伤。这个项目将产生重要的数据来定义突触失败
在AD患者和初步数据,以设计未来的研究,将AD患者的临床研究,
基础科学的机械发现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kamalini Gayathree Ranasinghe其他文献
Kamalini Gayathree Ranasinghe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kamalini Gayathree Ranasinghe', 18)}}的其他基金
Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
- 批准号:
10377356 - 财政年份:2019
- 资助金额:
$ 48.4万 - 项目类别:
Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
- 批准号:
9916699 - 财政年份:2019
- 资助金额:
$ 48.4万 - 项目类别:
Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
- 批准号:
10623150 - 财政年份:2019
- 资助金额:
$ 48.4万 - 项目类别:
Spatiotemporal Patterns of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的时空模式
- 批准号:
9051982 - 财政年份:2016
- 资助金额:
$ 48.4万 - 项目类别:
Spatiotemporal Patterns of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的时空模式
- 批准号:
9231998 - 财政年份:2016
- 资助金额:
$ 48.4万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 48.4万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 48.4万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 48.4万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 48.4万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 48.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 48.4万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 48.4万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 48.4万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 48.4万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 48.4万 - 项目类别:
Miscellaneous Programs